RU2693484C1 - Антагонисты гастрина для лечения и профилактики остеопороза - Google Patents

Антагонисты гастрина для лечения и профилактики остеопороза Download PDF

Info

Publication number
RU2693484C1
RU2693484C1 RU2016124538A RU2016124538A RU2693484C1 RU 2693484 C1 RU2693484 C1 RU 2693484C1 RU 2016124538 A RU2016124538 A RU 2016124538A RU 2016124538 A RU2016124538 A RU 2016124538A RU 2693484 C1 RU2693484 C1 RU 2693484C1
Authority
RU
Russia
Prior art keywords
gastrin
bone
hypergastrinemia
animals
cells
Prior art date
Application number
RU2016124538A
Other languages
English (en)
Russian (ru)
Other versions
RU2016124538A (ru
Inventor
Марк КИДД
Ирвин Марк МОДЛИН
Original Assignee
СиЭль БАЙОСАЕНСИЗ ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52118000&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2693484(C1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by СиЭль БАЙОСАЕНСИЗ ЭлЭлСи filed Critical СиЭль БАЙОСАЕНСИЗ ЭлЭлСи
Publication of RU2016124538A publication Critical patent/RU2016124538A/ru
Application granted granted Critical
Publication of RU2693484C1 publication Critical patent/RU2693484C1/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU2016124538A 2013-11-22 2014-11-21 Антагонисты гастрина для лечения и профилактики остеопороза RU2693484C1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361907980P 2013-11-22 2013-11-22
US61/907,980 2013-11-22
PCT/US2014/066832 WO2015077572A1 (en) 2013-11-22 2014-11-21 Gastrin antagonists (eg yf476, netazepide) for treatment and prevention of osteoporosis

Publications (2)

Publication Number Publication Date
RU2016124538A RU2016124538A (ru) 2017-12-27
RU2693484C1 true RU2693484C1 (ru) 2019-07-03

Family

ID=52118000

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016124538A RU2693484C1 (ru) 2013-11-22 2014-11-21 Антагонисты гастрина для лечения и профилактики остеопороза

Country Status (14)

Country Link
US (1) US10709714B2 (enExample)
EP (1) EP3071206B1 (enExample)
JP (1) JP6502939B2 (enExample)
KR (1) KR102254957B1 (enExample)
CN (1) CN106163527A (enExample)
AU (1) AU2014352875B2 (enExample)
BR (1) BR112016011727A2 (enExample)
CA (1) CA2929858C (enExample)
DK (1) DK3071206T3 (enExample)
ES (1) ES2870538T3 (enExample)
MX (1) MX2016006657A (enExample)
PL (1) PL3071206T3 (enExample)
RU (1) RU2693484C1 (enExample)
WO (1) WO2015077572A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10881667B2 (en) 2018-10-30 2021-01-05 City University Of Hong Kong Method and composition for treating epilepsy
US11285161B2 (en) 2019-04-26 2022-03-29 City University Of Hong Kong Method and composition for treating mental disorder and pain associated with nerve damage
CN110935005A (zh) * 2019-11-19 2020-03-31 宁波大学 一种丙谷二肽的新用途
CN115770266B (zh) * 2023-01-30 2023-05-09 云南中医药大学 一种用于治疗绝经后骨质疏松的药物组合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005007107A2 (en) * 2003-07-11 2005-01-27 University Of Massachusetts Histamine and cck2/gastrin receptor blockade in the treatment of acid-peptic disease and cancer
RU2379043C2 (ru) * 2007-08-02 2010-01-20 Закрытое акционерное общество "Биологические исследования и системы" Фармацевтическая композиция для профилактики и лечения остеопороза у женщин в период менопаузы

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4992437A (en) 1987-12-22 1991-02-12 Yoshitomi Pharmaceutical Industries, Ltd. Thienodiazepine compounds and their pharmaceutical use
JPH0374328A (ja) 1989-08-04 1991-03-28 Warner Lambert Co 薬学的活性を有する中枢コレシストキニン拮抗剤
US5399565A (en) 1990-07-17 1995-03-21 Eli Lilly And Company Pyrazolidinone CCK and gastrin antagonists and pharmaceutical formulations therof
JPH07119217B2 (ja) 1990-12-25 1995-12-20 山之内製薬株式会社 新規ベンゾジアゼピン誘導体
JPH06509095A (ja) 1991-07-12 1994-10-13 ワーナー−ランバート・コンパニー パニック発作の治療に有用なコレシストキニン拮抗薬
WO1993007129A1 (fr) 1991-10-11 1993-04-15 Yoshitomi Pharmaceutical Industries, Ltd. Medicament utilise pour traiter l'osteoporose et compose de diazepine
WO1993012817A1 (en) 1991-12-20 1993-07-08 Warner-Lambert Company Therapeutic combinations useful in the treatment of gastroesophageal reflux disease
IL104853A (en) 1992-02-27 1997-11-20 Yamanouchi Pharma Co Ltd Benzodiazepine derivatives, their preparation and pharmaceutical compositions containing them
TW281669B (enExample) 1993-02-17 1996-07-21 Chugai Pharmaceutical Co Ltd
GB2282595A (en) 1993-08-25 1995-04-12 Yamanouchi Pharma Co Ltd Benzodiazepine derivatives
IT1261255B (it) 1993-09-09 1996-05-09 Rotta Research Lab Derivati acidi poliamidici ad attivita' antigastrinica, procedimento per la loro preparazione e loro uso farmaceutico.
US5750353A (en) 1995-12-11 1998-05-12 New England Medical Center Hospitals, Inc. Assay for non-peptide agonists to peptide hormone receptors
CA2239293A1 (en) 1995-12-11 1997-06-19 New England Medical Center Hosptials, Inc. Assay for and uses of peptide hormone receptor ligands
US5922883A (en) 1996-04-03 1999-07-13 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
CA2287872C (en) 1997-05-12 2010-07-27 Aphton Corporation Immunogenic compositions to the cck-b/gastrin receptor and methods for the treatment of tumors
US20040001842A1 (en) 1997-05-12 2004-01-01 Dov Michaeli Immunogenic compositions to the CCK-B/gastrin receptor and methods for the treatment of tumors
JP2002515457A (ja) 1998-05-15 2002-05-28 アフトン コーポレーション 腫瘍治療のための併用療法
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
KR20010052570A (ko) 1998-06-04 2001-06-25 스티븐 에프. 웨인스톡 세포 유착을 억제하는 소염성 화합물
US6541669B1 (en) 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
ATE283840T1 (de) 1999-01-29 2004-12-15 Chugai Pharmaceutical Co Ltd Chondrogonese promotoren und indolin-2-on derivate
HK1045306A1 (zh) 1999-06-03 2002-11-22 Abbott Laboratories 抑制细胞黏附的抗炎化合物
US20030191279A1 (en) 1999-08-27 2003-10-09 Goldstein Steven Wayne Urea derivatives useful as anticancer agents
US6844367B1 (en) 1999-09-17 2005-01-18 Millennium Pharmaceuticals, Inc. Benzamides and related inhibitors of factor Xa
RU2260009C2 (ru) 1999-11-05 2005-09-10 Сосьете Де Консей Де Решерш Э Д'Аппликасьон Сьентифик (С.К.Р.А.С.) Новые гетероциклические соединения и их применение в качестве лекарственных средств
JP2003513995A (ja) 1999-11-19 2003-04-15 アクスクシーマ ファルマシューティカルス アクチェンゲゼルシャフト ヘリコバクターピロリにより誘発される胃腸疾患の阻害剤
WO2001077685A2 (en) 2000-04-10 2001-10-18 The General Hospital Corporation Diagnosis and treatment of gastrointestinal disease
AU2001273040A1 (en) 2000-06-27 2002-01-08 Du Pont Pharmaceuticals Company Factor xa inhibitors
JP2005508838A (ja) 2001-03-23 2005-04-07 アフトン コーポレーション 膵癌の組合せ治療
US20040138285A1 (en) 2001-04-27 2004-07-15 Makoto Okazaki Chondrogenesis promoters
US20090191232A1 (en) 2001-05-04 2009-07-30 Gevas Philip C Combination therapy for the treatment of tumors
CA2445477A1 (en) 2001-05-11 2002-11-21 Yamanouchi Pharmaceutical Co., Ltd. Antitumor agents
AUPR738301A0 (en) 2001-08-30 2001-09-20 Starpharma Limited Chemotherapeutic agents
JP2005513013A (ja) 2001-11-13 2005-05-12 ジェームズ・ブラック・ファウンデーション・リミテッド ガストリンおよびコレシストキニンのレセプタ・リガンドとしてのベンゾトリアゼピン
US20050176796A1 (en) 2002-02-19 2005-08-11 D'alessio Roberto Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents
DE10207037A1 (de) 2002-02-20 2003-08-28 Bayer Cropscience Gmbh 2-Amino-4-bicyclyamino-6H-1,3.5-triazine, Verfahren zu deren Herstellung und deren Verwendung als Herbizide und Pflanzenwachstumsregulatoren
UA79804C2 (en) 2002-07-03 2007-07-25 Janssen Pharmaceutica Nv Cck-1 receptor modulators
US20030049698A1 (en) 2002-10-08 2003-03-13 Wang Timothy C. Diagnosis and treatment of gastrointestinal disease
US7241759B2 (en) 2003-03-28 2007-07-10 Janssen Pharmaceutica N.V. Benzo[1,2,5]thiadiazole compounds
WO2004101533A1 (en) 2003-05-12 2004-11-25 Janssen Pharmaceutica, N.V. 1, 3, 4-benzotriazepin-2-one salts and their use as cck receptor ligands
GB0310865D0 (en) 2003-05-12 2003-06-18 Black James Foundation Gastrin and cholecystokinin receptor ligands
EA200600203A1 (ru) 2003-08-08 2006-08-25 Янссен Фармацевтика, Н. В. Производные 2-(хиноксалин-5-илсульфониламино)бензамида в качестве модуляторов сск2
WO2005090319A1 (en) 2004-03-19 2005-09-29 Arrow Therapeutics Limited Process for preparing benzodiazepines
US7429604B2 (en) 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
US7947833B2 (en) 2004-08-04 2011-05-24 Janssen Pharmaceutica Nv Preparation of quinoxaline compounds
JP2008514608A (ja) 2004-09-24 2008-05-08 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ スルホンアミド化合物
EP1817333A4 (en) 2004-10-12 2008-12-31 Janssen Pharmaceutica Nv CHOLECYSTOKININ-1 RECEPTOR MATERIALS OF DOGS AND THEIR USE
US20090239841A1 (en) 2004-10-27 2009-09-24 Hutchison Alan J Diaryl Ureas as CB1 Antagonists
EP1807390A4 (en) 2004-11-04 2008-07-02 Neurogen Corp ARYL ALKYL UREA AS CB1 ANTAGONISTS
GB0425196D0 (en) 2004-11-15 2004-12-15 Black James Foundation Gastrin and cholecystokinin receptor ligands
ATE405262T1 (de) 2004-12-17 2008-09-15 Pfizer Chroman-derivate als säurepumpenantagonisten
EP1839662B1 (en) 2005-01-19 2010-03-24 Zeria Pharmaceutical Co., Ltd. Antitumor agent
AR053713A1 (es) 2005-04-20 2007-05-16 Xenon Pharmaceuticals Inc Compuestos heterociclicos y sus usos como agentes terapeuticos
AU2006255047B2 (en) 2005-06-06 2011-09-15 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating sleep disorders
CA2608582A1 (en) 2005-06-14 2006-12-21 Pfizer Inc. Chromane substituted benzimidazole derivatives as acid pump antagonists
DE602005013372D1 (de) 2005-07-29 2009-04-30 Rottapharm Spa Kombination aus Itriglumid und PPI zur Behandlung von gastrointestinalen- und assozierten Krankheiten
WO2007026218A2 (en) 2005-09-01 2007-03-08 Pfizer Japan Inc. Chromane substituted 2-alkyl imidazopyridine derivatives and use thereof as acid pump antagonists
WO2007031860A1 (en) 2005-09-15 2007-03-22 Pfizer Japan Inc. Indane substituted benzimidazoles and their use as acid pump inhibitors
WO2007072142A2 (en) 2005-12-19 2007-06-28 Pfizer Japan Inc. Benzimidazole-5-carboxamide derivatives
BR122020004679B1 (pt) 2005-12-19 2021-09-21 Raqualia Pharma Inc Composição farmacêutica
BRPI0708808A2 (pt) 2006-03-17 2011-06-14 Raqualia Pharma Inc Derivados de cromano
EP2004631A1 (en) 2006-04-12 2008-12-24 Merck Patent GmbH N-oxides of heterocyclic substituted bisarylureas for treating kinase-mediated diseases
FR2901473B1 (fr) 2006-05-24 2010-08-13 Oreal Procede de defrisage des fibres keratiniques avec un moyen de chauffage et une amide
FR2901472B1 (fr) 2006-05-24 2010-08-13 Oreal Procede de defrisage des fibres keratiniques avec un moyen de chauffage et des agents denaturants
WO2008035195A1 (en) 2006-09-21 2008-03-27 Raqualia Pharma Inc. Benzimidazole derivatives as selective acid pump inhibitors
WO2008046082A2 (en) 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Use of heterocyclic compounds as therapeutic agents
WO2008059373A1 (en) 2006-11-17 2008-05-22 Raqualia Pharma Inc. Imidazo [1, 2-a] pyrazine derivatives and their use as acid pump antagonists
JP2008222557A (ja) 2007-03-08 2008-09-25 Kotobuki Seiyaku Kk ピロロ［３，２−ｄ］ピリミジン誘導体及びこれを有効成分とする医薬組成物
WO2008114123A1 (en) 2007-03-21 2008-09-25 Raqualia Pharma Inc. Spiro benzimidazole derivatives as acid pump inhibitors
WO2008124524A2 (en) 2007-04-03 2008-10-16 Janssen Pharmaceutica N.V. Aryl sulfonamide compounds as modulators of the cck2 receptor
WO2008124518A1 (en) 2007-04-03 2008-10-16 Janssen Pharmaceutica N.V. Oxo-dihydroisoindole sulfonamide compounds as modulators of the cck2 receptor
AU2008267444A1 (en) 2007-06-26 2008-12-31 Sanofi-Aventis A regioselective copper catalyzed synthesis of benzimidazoles and azabenzimidazoles
US20110105515A1 (en) 2007-08-07 2011-05-05 President And Fellows Of Harvard College Targeting the oncoprotein nucleophosmin
TW201011009A (en) 2008-09-15 2010-03-16 Priaxon Ag Novel pyrrolidin-2-ones
WO2010036316A1 (en) 2008-09-24 2010-04-01 Yangbo Feng Urea and carbamate compounds and analogs as kinase inhibitors
CN102333763A (zh) 2009-03-31 2012-01-25 善利亚新药工业股份有限公司 1,5-苯二氮䓬衍生物的制备方法
US8648080B2 (en) 2009-07-09 2014-02-11 Raqualia Pharma Inc. Acid pump antagonist for the treatment of diseases involved in abnormal gastrointestinal motility
WO2011036461A1 (en) 2009-09-24 2011-03-31 Centro Nacional De Investigaciones Oncόlogicas (Cnio) Fused imidazo [3, 2 - d] pyrazines as pi3 kinase inhibitors
AU2010303567B2 (en) 2009-10-06 2016-06-09 Millennium Pharmaceuticals, Inc Heterocyclic compounds useful as PDK1 inhibitors
US9181414B2 (en) 2009-11-13 2015-11-10 Plastipak Packaging, Inc. Oxygen scavengers, compositions comprising the scavengers, and articles made from the compositions
WO2011063164A2 (en) 2009-11-18 2011-05-26 Steady Sleep Rx Co., Inc. Sustained release cannabinoid medicaments
KR20130069640A (ko) 2010-04-23 2013-06-26 키네타, 인크. 항-바이러스 화합물
CN106107406B (zh) 2010-08-12 2020-06-09 弗门尼舍公司 提高甜味增强剂的稳定性的方法和包含稳定的甜味增强剂的组合物
MX2013005564A (es) 2010-11-18 2014-03-12 Pier Pharmaceuticals Medicamentos de canabinoides en bajas dosis.
US20120231083A1 (en) 2010-11-18 2012-09-13 The Board Of Trustees Of The University Of Illinois Sustained release cannabinoid medicaments
US20140031547A1 (en) 2010-12-14 2014-01-30 Electrophoretics Limited CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODE-GENERATIVE DISEASES SUCH AS TAUOPATHIES
WO2013017479A1 (en) 2011-07-29 2013-02-07 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
WO2013017480A1 (en) 2011-07-29 2013-02-07 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
CN104039801B (zh) 2011-11-07 2017-05-10 麻省理工学院 用于z选择性烯烃复分解的钨氧代亚烷基络合物
US10080805B2 (en) 2012-02-24 2018-09-25 Purdue Research Foundation Cholecystokinin B receptor targeting for imaging and therapy
WO2013158928A2 (en) 2012-04-18 2013-10-24 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
TWI610916B (zh) 2012-08-03 2018-01-11 廣東東陽光藥業有限公司 作爲丙型肝炎抑制劑的橋環化合物及其在藥物中的應用
US8952009B2 (en) 2012-08-06 2015-02-10 Amgen Inc. Chroman derivatives as TRPM8 inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005007107A2 (en) * 2003-07-11 2005-01-27 University Of Massachusetts Histamine and cck2/gastrin receptor blockade in the treatment of acid-peptic disease and cancer
RU2379043C2 (ru) * 2007-08-02 2010-01-20 Закрытое акционерное общество "Биологические исследования и системы" Фармацевтическая композиция для профилактики и лечения остеопороза у женщин в период менопаузы

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BOYCE M. et al. "Single oral doses of netazepide (YF476), a gastrin receptor antagonist, cause dose-dependent, sustained increases in gastric pH compared with placebo and ranitidine in healthy subjects". Aliment Pharmacol Ther. 2012 Jul; 36(2):181-9. *
SCHINKE T. et al. "Impaired gastric acidification negatively affects calcium homeostasis and bone mass". Nature Medicine, 2009, vol.15, no.6, pp.674-682. *
SCHINKE T. et al. "Impaired gastric acidification negatively affects calcium homeostasis and bone mass". Nature Medicine, 2009, vol.15, no.6, pp.674-682. BOYCE M. et al. "Single oral doses of netazepide (YF476), a gastrin receptor antagonist, cause dose-dependent, sustained increases in gastric pH compared with placebo and ranitidine in healthy subjects". Aliment Pharmacol Ther. 2012 Jul; 36(2):181-9. *

Also Published As

Publication number Publication date
MX2016006657A (es) 2016-10-12
PL3071206T3 (pl) 2022-01-17
KR102254957B1 (ko) 2021-05-25
RU2016124538A (ru) 2017-12-27
EP3071206B1 (en) 2021-02-17
ES2870538T3 (es) 2021-10-27
AU2014352875B2 (en) 2019-10-24
CN106163527A (zh) 2016-11-23
EP3071206A1 (en) 2016-09-28
JP2016538295A (ja) 2016-12-08
CA2929858C (en) 2022-03-29
CA2929858A1 (en) 2015-05-28
AU2014352875A8 (en) 2016-06-30
KR20160088891A (ko) 2016-07-26
BR112016011727A2 (pt) 2017-08-08
US10709714B2 (en) 2020-07-14
DK3071206T3 (da) 2021-05-25
US20150148339A1 (en) 2015-05-28
WO2015077572A1 (en) 2015-05-28
JP6502939B2 (ja) 2019-04-17
AU2014352875A1 (en) 2016-05-26

Similar Documents

Publication Publication Date Title
Lupsa et al. Bone health and osteoporosis
Bonani et al. Sclerostin blood levels before and after kidney transplantation
Henriksen et al. Four-month treatment with GLP-2 significantly increases hip BMD: a randomized, placebo-controlled, dose-ranging study in postmenopausal women with low BMD
John et al. AXT914 a novel, orally-active parathyroid hormone-releasing drug in two early studies of healthy volunteers and postmenopausal women
Bhattacharyya et al. Targeted inhibition of sclerostin for post-menopausal osteoporosis therapy: a critical assessment of the mechanism of action
Kashii et al. Romosozumab was not effective in preventing multiple spontaneous clinical vertebral fractures after denosumab discontinuation: a case report
Xu et al. Effects of different dosages of parathyroid hormone-related protein 1–34 on the bone metabolism of the ovariectomized rat model of osteoporosis
Mazid Helali et al. Cathepsin K inhibitors: a novel target but promising approach in the treatment of osteoporosis
Shapiro et al. The effect of intravenous pamidronate on bone mineral density, bone histomorphometry, and parameters of bone turnover in adults with type IA osteogenesis imperfecta
Matuszewska et al. Effects of long-term administration of pantoprazole on bone mineral density in young male rats
US20030109537A1 (en) Methods and materials for treating bone conditions
EP3071206B1 (en) Gastrin antagonists (eg yf476, netazepide) for treatment and prevention of osteoporosis
Mohanty et al. Molecular mechanisms and treatment strategies for estrogen deficiency-related and glucocorticoid-induced osteoporosis: a comprehensive review: S. Mohanty et al.
Pouilles et al. Effects of cyclical etidronate therapy on bone loss in early postmenopausal women who are not undergoing hormonal replacement therapy
Li et al. Oral administration of bovine lactoferrin accelerates the healing of fracture in ovariectomized rats
Mazokopakis et al. Changes of bone mineral density in pre-menopausal women with differentiated thyroid cancer receiving L‐thyroxine suppressive therapy
Liu et al. Changes of substance P-immunoreactive nerve fiber innervation density in the sublesional bones in young growing rats at an early stage after spinal cord injury
Jiang et al. An overview of osteoporosis management
Yahyavi et al. Effect of a single-dose denosumab on mineral homeostasis in infertile men: insights from a pilot intervention study and a randomized controlled trial
AU2017313842A1 (en) PPARgamma AGONIST FOR TREATMENT OF BONE DISORDERS
Li et al. Differential bone turnover in an angulated fracture model in the rat
Li-Yu Concerns on Medications Used in Osteoporosis
Zhu Targeting TGFβ1 Signaling: A Sustained-release, Monthly Intra-articular Injection Intervention for Early Osteoarthritis
Bellone et al. Zoledronic Acid Induces Early Changes of VEGF Levels in Women With Postmenopausal Osteoporosis
HK1230487A1 (en) Gastrin antagonists (eg yf476, netazepide) for treatment and prevention of osteoporosis